Allergy Therapeutics Capital Reinvestment Ratio
Allergy Therapeutics capital reinvestment ratio. Allergy Therapeutics (AGY) has a Capital Reinvestment Ratio of 0.31x as of December 2021, meaning it reinvests 0% of its operating cash flow (GBX3.71 Million) in capital expenditures (GBX1.15 Million). Check Allergy Therapeutics (AGY) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Allergy Therapeutics (2003–2021)
Capital reinvestment ratio of Allergy Therapeutics from 2003 to 2021. This chart tracks Allergy Therapeutics's Capital Reinvestment Ratio across 11 annual periods. Also explore AGY net asset momentum to track the company's year-over-year net asset growth rate.
Allergy Therapeutics Capital Reinvestment Ratio by Year (2003–2021)
Allergy Therapeutics capital reinvestment ratio by year from 2003 to 2021. For the full cash flow conversion analysis, see cash efficiency ratio of Allergy Therapeutics.
| Year | Reinvestment Ratio | Operating CF (GBX) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.30x | GBX8.52 Million | GBX2.56 Million | ▲ +45.0% |
| 2020 | 0.21x | GBX12.28 Million | GBX2.55 Million | ▼ -58.7% |
| 2019 | 0.50x | GBX5.60 Million | GBX2.81 Million | ▼ -94.0% |
| 2017 | 8.43x | GBX178.00K | GBX1.50 Million | ▲ +2312.2% |
| 2015 | 0.35x | GBX3.12 Million | GBX1.09 Million | ▼ -15.5% |
| 2014 | 0.41x | GBX2.17 Million | GBX898.00K | ▲ +22.4% |
| 2013 | 0.34x | GBX2.43 Million | GBX821.00K | ▼ -22.9% |
| 2012 | 0.44x | GBX2.88 Million | GBX1.26 Million | ▼ -56.1% |
| 2010 | 1.00x | GBX1.70 Million | GBX1.70 Million | ▲ +150.2% |
| 2004 | 0.40x | GBX1.91 Million | GBX760.00K | ▲ +105.8% |
| 2003 | 0.19x | GBX2.10 Million | GBX406.00K | — |